钆贝葡胺在新生儿及婴儿脑与脊柱MRI中的安全性与诊断效能
研究在2个影像中心回顾性纳入90例2岁以下儿童(含55例1岁以下),评估钆贝葡胺0.1 mmol/kg增强MRI的安全性,并由3名盲法独立读者前瞻性评估增强前后联合图像相对平扫的诊断准确性;结果显示不良事件均为非严重且与药物无关,增强后联合图像对肿瘤与非肿瘤鉴别及具体诊断的准确性显著提高,安全性良好。
要点
- 2岁以下儿童使用钆贝葡胺0.1 mmol/kg增强MRI,非严重不良事件发生率8.8%,均发生在给药24小时后且研究者判断与药物无关。
- 增强前后联合图像较平扫显著提高肿瘤与非肿瘤鉴别准确性(各读者91.0%-94.4% vs 75.3%-87.6%,P<.04)。
- 增强前后联合图像较平扫显著提高具体诊断准确率(66.3%-73.0% vs 52.8%-58.4%,P<.02)。
核心结论
- 钆贝葡胺用于儿童MR成像是安全且有效的。
研究设计与样本
- 回顾性纳入2个影像中心的90例2岁以下儿童(含55例1岁以下),行钆贝葡胺0.1 mmol/kg增强CNS MRI;安全性评估不良事件及可获得的48小时前后生命体征、心电图和实验室值;诊断效能由3名盲法独立读者前瞻性评估。
诊断标准与关键数值
- 肿瘤与非肿瘤鉴别准确性:增强前后联合图像各读者91.0%-94.4%,平扫75.3%-87.6%,差异显著(P<.04);具体诊断准确率:增强前后联合图像66.3%-73.0%,平扫52.8%-58.4%(P<.02);剂量≤0.08 mmol/kg与>0.08 mmol/kg组间诊断准确性无显著差异(P>.133)。
临床应用与阅片要点
- 作者结论认为钆贝葡胺用于儿童MR成像是安全且有效的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Contrast-enhanced MR imaging provides essential information for pediatric imaging applications. We evaluated gadobenate dimeglumine for contrast-enhanced MR imaging of infants younger than 2 years of age.
MATERIALS AND METHODS: Ninety children younger than 2 years of age (including 55 children younger than 1 year) who underwent enhanced MR imaging of the CNS with gadobenate dimeglumine at 0.1 mmol/kg body weight ± 25% by volume were retrospectively enrolled at 2 imaging centers. Safety data were assessed for adverse events and, when available, vital signs and electrocardiogram and clinical laboratory values obtained from 48 hours before until 48 hours after the MR imaging examination. The efficacy of gadobenate dimeglumine-enhanced MR imaging was evaluated prospectively by 3 blinded, unaffiliated readers in terms of the accuracy of combined pre- and postcontrast images relative to precontrast images alone for differentiation of tumor from non-neoplastic disease and the correct diagnosis of specific disease. Differences were tested using the McNemar test. A possible effect of dose on diagnostic accuracy was assessed using the Fisher exact test.
RESULTS: Nine nonserious adverse events were reported for 8 (8.8%) patients. Five adverse events occurred in patients 12 months of age or older. All events occurred at least 24 hours after gadobenate dimeglumine administration, and in each case, the investigating radiologist considered that there was no reasonable possibility of a relationship to gadobenate dimeglumine. No clinically meaningful changes in vital signs, electrocardiogram results, or laboratory parameters were reported. Accurate differentiation of tumor from non-neoplastic disease and exact matching of each specific MR imaging-determined diagnosis with the on-site final diagnosis were achieved in significantly more patients by each reader following evaluation of combined pre- and postcontrast images relative to precontrast images alone (91.0%-94.4% versus 75.3%-87.6%, P < .04, and 66.3%-73.0% versus 52.8%-58.4%, P < .02, respectively). No significant differences (P > .133) in diagnostic accuracy were noted between patients receiving ≤0.08 mmol/kg of gadobenate dimeglumine and patients receiving >0.08 mmol/kg of gadobenate dimeglumine.
CONCLUSIONS: Gadobenate dimeglumine is safe and effective for pediatric MR imaging.
引用
- Enterline DS, Martin KW, Parmar HA, et al. Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants. AJNR Am J Neuroradiol. 2019. PMID: 31727753. doi:10.3174/ajnr.A6319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。